An evaluation of torsemide in patients with heart failure and renal disease

2021 ◽  
Author(s):  
Anthony E. Peters ◽  
Robert J. Mentz ◽  
Tracy A. DeWald ◽  
Stephen J. Greene
Keyword(s):  
Heart Failure ◽  
Renal Disease ◽  
Patients With Heart Failure

scholarly journals Usefulness of Age, Creatinine and Ejection Fraction - Modification of Diet in Renal Disease Score for Predicting Survival in Patients with Heart Failure

2021 ◽  
Author(s):  
Rengin Cetin Guvenc ◽  
Tolga Sinan Guvenc ◽  
Yuksel Cavusoglu ◽  
Ahmet Temizhan ◽  
Mehmet Birhan YILMAZ
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Renal Disease ◽  
Independent Predictor ◽  
Disease Score ◽  
Risk Models ◽  
Patients With Heart Failure ◽  
Multiple Variables ◽  
One Year ◽  
Similar Accuracy

Background: While many risk models have been developed to predict prognosis in heart failure (HF), these models are rarely useful for the clinical practitioner as they include multiple variables that might be time-consuming to obtain, they are usually difficult to calculate and they may suffer from statistical overfitting. Present study aimed to investigate whether a simpler model, namely ACEF-MDRD score, could be used for predicting one-year mortality in HF patients. Methods: 748 cases within the SELFIE-HF registry had complete data to calculate ACEF-MDRD score. Patients were grouped into tertiles for analyses. Results: Significantly more patients within the ACEF-MDRDhigh tertile (30.0%) died within one year, as compared to other tertiles (10.8% and 16.1%, respectively, for ACEF-MDRDlow and ACEF-MDRDmed, p<0.001 for both comparisons). There was a stepwise decrease in one-year survival as ACEF-MDRD score increased (log-rank p<0.001). ACEF-MDRD was an independent predictor of survival after adjusting for other variables (OR: 1.14, 95%CI:1.04 – 1.24, p=0.006). ACEF-MDRD score offered similar accuracy to GWTG-HF score for prediction of one-year mortality (p=0.14). Conclusions: ACEF-MDRD is a predictor of mortality in patients with HF, and its usefulness is comparable to similar yet more complicated models.

Abstract 12810: Beta Blockers and Mortality Benefit in Patients With Heart Failure and End Stage Renal Disease on Hemodialysis

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Chakradhari Inampudi ◽  
Vlad Cotarlan
Keyword(s):  
Heart Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Beta Blockers ◽  
Systolic Heart Failure ◽  
Mortality Benefit ◽  
Survival Curves ◽  
Patients With Heart Failure ◽  
Stage Renal Disease ◽  
End Stage

Background: Post-hoc analysis of Randomized control trials have established safety and efficacy of Beta blockers (BB) in patients with systolic heart failure (HF) and mild to moderate Chronic kidney disease (CKD). However, the mortality benefit in patients with advanced CKD especially those approaching end stage renal disease (ESRD) is limited. The study was sought to identify mortality benefit in patients with Heart failure (HF) and ESRD who progressed to dialysis. Methods: Using electronic medical records, we identified 1,817 patients with end stage renal dialysis(ESRD) who progressed to dialysis over a 6 year period between 2004 and 2011. Kaplan Meyer survival curves were used to assess the association between BB use and mortality. Results: Of 1817 patients (mean age 61+/-15, 57% males) with ESRD who progressed to dialysis, 1329 (73.1%) were treated with BB and 488 (26.5%) were never treated with a BB. Kaplan Meyer Survival curves showed that patients who received treatment with BB had better survival than patients who were never treated with BB despite more HTN and diabetes present in the former group (mean survival time 4.9 years versus 4.4 years, p<0.001, Fig 1). Survival graphs were similar for those with an encounter diagnosis of HF (n=547, Fig 2) and those without an encounter diagnosis of HF (n=1270, graph not shown) with stronger association between BB and survival among those with HF (mean survival 3.1 versus 4.8 years, p=0.001, Fig 2). Conclusion: Treatment with BB is associated with improved survival in heart failure patients with ESRD who progressed to dialysis.

scholarly journals Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease

2020 ◽  
Vol 7 (3) ◽  
pp. 1125-1129 ◽  
Author(s):  
Seonhwa Lee ◽  
Jaewon Oh ◽  
Hyoeun Kim ◽  
Jaehyung Ha ◽  
Kyeong‐hyeon Chun ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Renal Disease ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
End Stage

Prognostic Role of Hyponatremia in Heart Failure Patients Depending on Renal Disease: Clinical Evidence

Cardiology ◽  
2019 ◽  
Vol 144 (1-2) ◽  
pp. 1-8
Author(s):  
José Carlos Arévalo-Lorido ◽  
Juana Carretero-Gómez ◽  
Nicolás Roberto Robles ◽  
Pau Llácer ◽  
Margarita Carrera ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Insufficiency ◽  
Renal Disease ◽  
National Registry ◽  
Normal Serum ◽  
Patients With Heart Failure ◽  
And Gender ◽  
Normal Serum Sodium

Aim: Hyponatremia is very often associated with renal disease in patients with heart failure (HF) and, when present, determines a poor outcome. We investigated the role of hyponatremia in HF patients in whom the presence or absence renal insufficiency was accurately predefined. Methods: This was a cohort study based on the Spanish National Registry on Heart Failure (RICA), a multicenter, prospective registry that enrolls patients admitted for decompensated HF who were subsequently followed up for 1 year. We classified patients into 4 groups according to the presence or absence of renal disease defined by the hematocrit, urea, and gender formula (HUGE) and then according to the presence of hyponatremia (Na ≤135 mEq/L). Results: A total of 3,478 patients were included. Hyponatremia was more prevalent in the group with renal disease (22.1%) than without (18.4%). During admission, both groups with hyponatremia had more complications than those with normal serum sodium. During the 1-year follow-up, patients with hyponatremia and renal disease had a significantly worse outcome (HF mortality and readmission), HR 1.87, 95% CI 1.54–2.29, p < 0.001, compared to those with hyponatremia without renal disease, HR 1.01, 95% CI 0.79–1.3, p = 0.94. Conclusions: Hyponatremia is more prevalent in patients with renal insufficiency, and outcome is poorest when both renal disease and hyponatremia coexist. Patients with hyponatremia without renal disease show no differences in outcome compared to those without hyponatremia.

Sign in / Sign up

Export Citation Format

Share Document